Skip to main content Skip to main navigation menu Skip to site footer
MedNext Journal of Medical and Health Sciences
Review
DOI: 10.54448/mdnt23101
Submitted: 27-01-2023
Published: 27-01-2023

Major clinical outcomes of melatonin regulation in obesity: a systematic review

Empresarial Thygunan, João Pessoa, Paraíba, Brazil
Obesity Metabolic syndrome Type 2 diabetes mellitus Melatonin Regulation

Abstract

Introduction: In the scenario of non-communicable chronic diseases, obesity has briefly impacted the global population, causing serious public health problems. There are approximately 2.0 billion overweight and obese people in the world. Brazil ranks fifth in the world with approximately 18.0 million people. Research has advanced on the physiological role of melatonin (MEL) as a therapeutic agent for the treatment of obesity. Objective: It was to highlight the main clinical outcomes of melatonin regulation in obesity through a systematic review of the literature. Methods: The present study followed a concise systematic review model, following the systematic review rules (PRISMA). The literary search process was carried out from September to October 2022 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar. The low quality of evidence was attributed to case reports, editorials, and brief communications, according to the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: It was founded 139 studies were submitted to the eligibility analysis, then, 46 of the 54 total studies were selected for this systematic review. According to the GRADE instrument, most studies showed homogeneity in their results, with I2 =98.4% >50%. Studies have shown an important role for melatonin in metabolic diseases such as obesity, type 2 diabetes mellitus, and metabolic syndrome. It is possible to define some pathological syndromes related to MEL and discuss general guidelines for clinical therapy. However, there is still no consensus on the possible role of melatonin as an adjuvant in the treatment of metabolic diseases. More studies are needed to define the possible risks and benefits of melatonin as a therapeutic agent. Furthermore, several precautions must be taken into account, such as restricting the administration of chronic melatonin to the night, carefully choosing the time of administration according to the desired effect, and adapting the dosage and formulation individually to build a melatonin blood profile that mimics the physiological and ends early in the morning.

Metrics

Metrics Loading ...

References

  1. WHO- World Health Organization. Available at: https://www.sbcbm.org.br/endoscopye-obesidade/ Accessed in October 2022.
  2. IBGE- Brazilian Institute of Geography and Statistics. Available at: http://www.ibge.gov.br. Accessed October 2022.
  3. Guan Q, Wang Z, Cao J, Dong Y, Chen Y. Mechanisms of Melatonin in Obesity: A Review. Int J Mol Sci. 2021 Dec 25;23(1):218. doi: 10.3390/ijms23010218.
  4. Pivonello C, Negri M, Patalano R, Amatrudo F, Montò T, Liccardi A, Graziadio C, Muscogiuri G, Pivonello R, Colao A. The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. Obes Rev. 2022 Mar;23(3):e13390. doi: 10.1111/obr.13390.
  5. Xu L, Li D, Li H, Zhang O, Huang Y, Shao H, Wang Y, Cai S, Zhu Y, Jin S, Ding C. Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high-fat diet. Nutr Diabetes. 2022 Oct 7;12(1):42. doi: 10.1038/s41387-022-00222-2.
  6. Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol. 2019 Feb;15(2):105-125. doi: 10.1038/s41574-018-0130-1.
  7. Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo I, CotoMontes A. Therapeutic potential of melatonin related to its role as an autophagy regulator: A review. J Pineal Res. 2019 Jan;66(1):e12534. doi: 10.1111/jpi.12534. Epub 2018 Nov 26.
  8. Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2017 May;60(5):808-822. doi: 10.1007/s00125-016-4175-1. Epub 2016 Dec 162. doi: 10.1016/j.ijom.2022.05.014.
  9. Challet E. Keeping circadian time with hormones. Diabetes Obes Metab. 2015 Sep;17 Suppl 1:76-83. doi: 10.1111/dom.12516.
  10. Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M, Thumser AE, Raynaud FI, Skene DJ. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10761-6. doi: 10.1073/pnas.1402663111. Epub 2014 Jul 7.
  11. Al-Sarraf IAK, Kasabri V, Akour A, Naffa R. Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study. Horm Mol Biol Clin Investig. 2018 May 29;35(2). pii: /j/hmbci.2018.35.issue-2/hmbci-2018-0016/hmbci2018-0016.xml. doi: 10.1515/hmbci-2018-0016.
  12. Baron KG, Reid KJ, Wolfe LF, Attarian H, Zee PC. Phase Relationship between DLMO and Sleep Onset and the Risk of Metabolic Disease among Normal Weight and Overweight/Obese Adults. J Biol Rhythms. 2018 Feb;33(1):76-83. doi: 10.1177/0748730417745914. Epub 2017 Dec 20.
  13. Cardinali DP, Vigo DE. Melatonin, mitochondria, and the metabolic syndrome. Cell Mol Life Sci. 2017 Nov;74(21):3941-3954. doi: 10.1007/s00018-017-2611-0. Epub 2017 Aug 17.
  14. Rao PV. Type 2 diabetes in children: clinical aspects and risk factors. Indian J Endocrinol Metab 2015; 19(Suppl1): S47-S50.
  15. Milcu I, Nanu L, Marcean R et al. The action of pineal extract and epiphysectomy on hepatic and muscular glycogen after prolonged infusion of glucose. Stud Cercet Endocrinol 1963; 14: 651-655.
  16. Zanquetta MM, Seraphim PM, Sumida DH et al. Calorie restrictionreduces pinealectomyinduced insulin resitance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res 2003; 35: 141-148.
  17. Ghosh G, De K, Maity S et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res 2007; 42: 343-350.
  18. 18. McMullan CJ, Schernhammer ES, Rimm EB et al. Melatonin secretion and the incidence of tye 2 diabetes. JAMA 2013; 109(13): 1388-1396.
  19. Chen W, Cao H, Lu QY et al. Urinary 6-sulfatoxymelatonin level in diabetic retinophaty patients with type 2 diabetes. Int J Clin Exp Pathol 2014; 7(7): 4317-4322.
  20. Chen W, Cao H, Lu QY et al. Urinary 6-sulfatoxymelatonin level in diabetic retinophaty patients with type 2 diabetes. Int J Clin Exp Pathol 2014; 7(7): 4317-4322.
  21. National Sleep Foundation. 2002 "Sleep in America" Poll. Washington DC: National Sleep Foundation, 2002.
  22. Vorona R, Winn M, Babineau T et al. Overweight and obese patients in a primary care population report less sleep than patients wiht a normal body mass index. Arch Inter Med 2005; 165: 25-30.
  23. Dempsey JA, Veasay SC, Morgan BJ et al. Pathophysiologicy of sleep apnea. Physiol Rev 2010; 90(1): 47-112.
  24. Lucassen EA, Rother KI, Cizza G. Interacting epidemics? Sleep curtailment, insulin resistance, and obesity. Ann NYAcad Sci 2012; 1264: 110-134.
  25. Amstrup AK, Sikjaer T, Pedersen SB, Heickendorff L, Mosekilde L, Rejnmark L. Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2016;84(3):342–347.
  26. Romo-Nava F, Alvarez-Icaza Gonz´ alez D, Fres´ anOrellana A, Saracco Alvarez R, Becerra-Palars C, Moreno J, Ontiveros Uribe MP, Berlanga C, Heinze G, Buijs RM. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, doubleblind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–421.
  27. Agahi M, Akasheh N, Ahmadvand A, Akbari H, Izadpanah F. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial. Diabetes Metab Syndr. 2018;12(1):9–15.
  28. Kamath A, Rather ZA. Melatonin for atypical antipsychotic-induced metabolic adverse effects: a meta-analysis of randomized controlled trials. BioMed Res Int. 2018;2018:4907264.
  29. Mohammadi-Sartang M, Ghorbani M, Mazloom Z. Effects of melatonin supplementation on blood lipid concentrations: a systematic review and metaanalysis of randomized controlled trials [published online ahead of print 16 November 2017]. Clin Nutr. doi: 10.1016/j.clnu.2017.11.003.
  30. Mostafavi SA, Solhi M, Mohammadi MR, Akhondzadeh S. Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: a randomized, double-blind, placebocontrolled trial. J Child Adolesc Psychopharmacol. 2017;27(5):440–444.
  31. Zheng C, Dalla Man C, Cobelli C, Groop L, Zhao H, Bale AE, Shaw M, Duran E, Pierpont B, Caprio S, Santoro N. A common variant in the MTNR1b gene is associated with increased risk of impaired fasting glucose (IFG) in youth with obesity. Obesity (Silver Spring). 2015;23:1022–1029.
  32. Zhan Y, Li C, Gao Q, Chen J, Yu S, Liu SG. Association between the rs4753426 polymorphism in MTNR1B with fasting plasma glucose level and pancreatic b-cell function in gestational diabetes mellitus. Genet Mol Res. 2015;14(3): 8778–8785.
  33. Lane JM, Chang AM, Bjonnes AC, Aeschbach D, Anderson C, Cade BE, Cain SW, Czeisler CA, Gharib SA, Gooley JJ, Gottlieb DJ, Grant SF, Klerman EB, Lauderdale DS, Lockley SW, Munch M, Patel S, Punjabi NM, Rajaratnam SM, Rueger M, St Hilaire MA, Santhi N, Scheuermaier K, Van Reen E, Zee PC, Shea SA, Duffy JF, Buxton OM, Redline S, Scheer FA, Saxena R. Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonina physiology. Diabetes. 2016;65(6):1741–1751.
  34. Bonnefond A, Froguel P. The case for too little melatonin signalling in increased diabetes risk. Diabetologia. 2017;60(5):823–825. 388.
  35. Bonnefond A, Karamitri A, Jockers R, Froguel P. The difficult journey from genomewide association studies to pathophysiology: the melatonin receptor 1B (MT2) paradigm. Cell Metab. 2016;24(3): 345–347.
  36. Mulder H. Melatonin signalling and type 2 diabetes risk: too little, too much or just right? Diabetologia. 2017;60(5):826–829.
  37. Tarnowski M, Malinowski D, Safranow K, Dziedziejko V, Pawlik A. MTNR1A and MTNR1B gene polymorphisms in women with gestational diabetes. Gynecol Endocrinol. 2017;33(5): 395–398.
  38. Touitou Y, Reinberg A, Touitou D. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption. Life Sci. 2017 Mar 15;173:94-106. doi: 10.1016/j.lfs.2017.02.008.
  39. Posadzki PP, Bajpai R, Kyaw BM, Roberts NJ, Brzezinski A, Christopoulos GI, Divakar U, Bajpai S, Soljak M, Dunleavy G, Jarbrink K, Nang EEK, Soh CK, Car J. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Med. 2018;16(1):18.
  40. Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, Isomaa B, Östman B, Söderström J, Pesonen AK, Martikainen S, Räikkönen K, Forsén T, Hakaste L, Almgren P, Storm P, Asplund O, Shcherbina L, Fex M, Fadista J, Tengholm A, Wierup N, Groop L, Mulder H. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. Cell Metab. 2016 Jun 14;23(6):1067-1077. doi: 10.1016/j.cmet.2016.04.009.
  41. J. Cipolla-Neto, F. G. Amaral, S. C. Afeche2, D. X. Tan, R. J. Reiter. Melatonin, energy metabolism, and obesity: a review. J. Pineal Res. 2014, 56:371–381.
  42. Fernanda G. Amaral, Ariane O. Turati1, Mark Barone, Julieta H. Scialfa, Daniella do Carmo Buonfiglio, Rafael Peres, Rodrigo A. Peliciari-Garcia, Solange C. Afeche , Larissa Lima , Cristoforo Scavone, Silvana Bordin, Russel J. Reiter, Luiz Menna-Barreto, José Cipolla-Neto. Melatonin synthesis impairment as a new deleterious outcome of diabetesderived hyperglycemia. J. Pineal Res. 2014, 57:67–79.
  43. Moshe Laudon, Anat Frydman-Marom. Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders. Int. J. Mol. Sci., 2014, 15: 15924-15950.
  44. Ewa Walecka-Kapica, Jan Chojnacki, Agnieszka Stępień, Patrycja Wachowska-Kelly, Grażyna Klupińska and Cezary Chojnacki. Melatonin and Female Hormone Secretion in Postmenopausal Overweight Women. Int. J. Mol. Sci., 2015,16:1030-1042.
  45. Thomas Roth, Tali Nir, Nava Zisapel. Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial. Nature and Science of Sleep,2015, 7: 13–23.
  46. Nishi T, Saeki K, Obayashi K, Miyata K, Tone N, Tsujinaka H, Yamashita M, Masuda N, Mizusawa Y, Okamoto M, Hasegawa T, Maruoka S, Ueda T, Kojima M, Matsuura T, Kurumatani N, Ogata N. The effect of blue-blocking intraocular lenses on circadian biological rhythm: protocol for a randomised controlled trial (CLOCK-IOL colour study). BMJ Open. 2015 May 12;5(5):e007930. doi: 10.1136/bmjopen-2015-007930.

How to Cite

Ribeiro, D. dos S. (2023). Major clinical outcomes of melatonin regulation in obesity: a systematic review. MedNEXT Journal of Medical and Health Sciences, 4(1). https://doi.org/10.54448/mdnt23101